Page last updated: 2024-12-10

sulfosuccinimidyl 4-(n-maleimidomethyl)cyclohexane-1-carboxylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID4618795
SCHEMBL ID45106
SCHEMBL ID4620757
MeSH IDM0194567

Synonyms (17)

Synonym
1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid
AKOS015900722
SCHEMBL45106
SCHEMBL4620757
sulfosuccinimidyl 4-(n-maleimidomethyl)cyclohexane-1-carboxylate
AKOS027257119
sulfosuccinimidyl 4-maleimidomethylcyclohexane carboxylate
1286837-77-1
1-((1r,4r)-4-((2,5-dioxo-2h-pyrrol-1(5h)-yl)methyl)cyclohexanecarbonyloxy)-2,5-dioxopyrrolidine-3-sulfonic acid
FPKVOQKZMBDBKP-UHFFFAOYSA-N
103708-09-4
CS-0105018
HY-126503
trans-sulfo-smcc
trans-1-((4-((2,5-dioxo-2,5-dihydro-1h-pyrrol-1-yl)methyl)cyclohexane-1-carbonyl)oxy)-2,5-dioxopyrrolidine-3-sulfonic acid
cyclohexanecarboxylic acid, 4-[(2,5-dihydro-2,5-dioxo-1h-pyrrol-1-yl)methyl]-, 2,5-dioxo-3-sulfo-1-pyrrolidinyl ester, trans-
1-((4-((2,5-dioxo-2,5-dihydro-1h-pyrrol-1-yl)methyl)cyclohexane-1-carbonyl)oxy)-2,5-dioxopyrrolidine-3-sulfonic acid

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" We also observed that crosslinking formed within the collagen scaffolds with excess dosage of Sulfo-SMCC, which improved the biological performance of collagen scaffolds together with growth factors."( Improved performance of collagen scaffolds crosslinked by Traut's reagent and Sulfo-SMCC.
Cheng, X; Deng, F; He, Q; Hu, X; Li, X; Li, Y; Liu, Y, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (21.74)18.2507
2000's2 (8.70)29.6817
2010's15 (65.22)24.3611
2020's1 (4.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]